Document Detail


Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.
MedLine Citation:
PMID:  20669312     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Coenzyme Q10 (CoQ(10)), a potential neuroprotective compound, was previously investigated at a dosage of 600 mg/day in Huntington's disease (HD) patients and demonstrated a trend toward slowing disease progression. Higher CoQ(10) dosages may prove beneficial. We investigated the tolerability and blood levels associated with 1,200, 2,400, and 3,600 mg/day of CoQ(10) in HD and healthy subjects. Twenty-eight subjects (20 HD, 8 healthy) enrolled in a 20-week open-label trial. Subjects started on 1,200 mg/day of CoQ(10), increasing every 4 weeks by 1,200 mg to a maximum dosage of 3,600 mg/day. Monthly evaluations included review of adverse events and CoQ(10) blood levels. Twenty-three subjects (82%) achieved the target dosage of 3,600 mg/day. Six subjects (2 healthy, 4 HD) withdrew prematurely (gastrointestinal (GI) symptoms in 3, worsening HD in 2, and 1 because of a fall). All three serious adverse events occurred in a single subject, and were deemed unrelated to CoQ(10). The most common adverse events seen were GI symptoms. Mean (± SD) CoQ10 blood levels achieved over the course of the trial were as follows: 1.26 ± 1.27 μg/mL (baseline, n = 28), 5.59 ± 2.24 μg/mL (1,200 mg/day, week 4, n = 26), 6.38 ± 3.25 μg/mL (2,400 mg/day, week 8, n = 25), 7.49 ± 4.09 μg/mL (3,600 mg/day, week 12, n = 23), and 6.78 ± 3.36 μg/mL (3,600 mg/day, week 20, n = 20). CoQ(10) was well tolerated with over 80% of subjects achieving the target dosage. Dosages of 2,400 mg/day may provide the best balance between tolerability and blood level achieved. Further studies examining the efficacy of 2,400 mg/day are planned.
Authors:
; H Christopher Hyson; Karl Kieburtz; Ira Shoulson; Michael McDermott; Bernard Ravina; Elisabeth A de Blieck; Merit E Cudkowicz; Robert J Ferrante; Peter Como; Sam Frank; Carol Zimmerman; Merit E Cudkowicz; Kimberly Ferrante; Kristyn Newhall; Danna Jennings; Tammie Kelsey; Francis Walker; Vicki Hunt; Susan Daigneault; Michele Goldstein; Joseph Weber; Arthur Watts; M Flint Beal; Susan E Browne; Linda J Metakis
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Movement disorders : official journal of the Movement Disorder Society     Volume:  25     ISSN:  1531-8257     ISO Abbreviation:  Mov. Disord.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-14     Completed Date:  2010-12-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8610688     Medline TA:  Mov Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1924-8     Citation Subset:  IM    
Copyright Information:
© 2010 Movement Disorder Society.
Affiliation:
University of Western Ontario, London, ON, Canada. chyson@uwo.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Analysis of Variance
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Toxicity
Female
Humans
Huntington Disease / drug therapy*
Male
Treatment Outcome
Ubiquinone / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
1339-63-5/Ubiquinone; 303-98-0/coenzyme Q10

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.
Next Document:  The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson...